NeuroPace Gestion
Gestion contrôle des critères 3/4
Le PDG NeuroPace est Joel Becker, nommé en Jul2023, a un mandat de 2.92 ans. La rémunération annuelle totale est $ 2.41M, composée du salaire de 23.6% et des bonus 76.4%, y compris les actions et options de la société. détient directement 0.41% des actions de la société, d'une valeur de $ 2.20M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 1.5 ans et 4.9 ans.
Informations clés
Joel Becker
Directeur général
US$2.4m
Rémunération totale
| Pourcentage du salaire du PDG | 23.56% |
| Durée du mandat du directeur général | 2.9yrs |
| Propriété du PDG | 0.4% |
| Durée moyenne d'occupation des postes de direction | 1.5yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 4.9yrs |
Mises à jour récentes de la gestion
Recent updates
Mise à jour du récit • Jun 02
NPCE: Strong Prescriber Momentum And 2026 Guidance Will Support More Optimistic Outlook
Narrative Update on NeuroPace The analyst price target for NeuroPace has moved from $19 to $20. Analysts point to stronger prescriber and patient pipeline trends and higher 2026 revenue guidance for the core RNS business as key drivers of this change.Article d’analyse • May 15
NeuroPace, Inc. (NASDAQ:NPCE) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
It's been a sad week for NeuroPace, Inc. ( NASDAQ:NPCE ), who've watched their investment drop 18% to US$15.79 in the...
Mise à jour du récit • Apr 30
NPCE: Future Returns Will Reflect Trial Data Strength And Execution Risk
Analysts have lifted their price target on NeuroPace from $15.63 to $18.00, citing updated expectations for revenue growth and profit margins, as well as a higher future P/E multiple following recent Street research coverage. Analyst Commentary The latest Street research on NeuroPace reflects constructive top line expectations alongside a watchful stance on execution and valuation risk.
Mise à jour du récit • Apr 15
NPCE: Refreshed Growth Assumptions And Richer P E Outlook Will Support Upside
Analysts have increased their average price target on NeuroPace by $1, citing updated assumptions that include slightly stronger revenue growth, a revised discount rate, a lower projected profit margin and a higher future P/E multiple. Analyst Commentary Bullish analysts are highlighting NeuroPace as a name where recent research work has led to more constructive views on both execution and valuation.Mise à jour du récit • Apr 01
NPCE: Higher Margin Conviction And Reaffirmed Guidance Will Support More Optimistic Outlook
Analysts have modestly increased their price target on NeuroPace by $1, citing refreshed assumptions around long term profit margins and a slightly higher future P/E multiple. Analyst Commentary Bullish Takeaways Bullish analysts see room for long term margin improvement, which supports their willingness to apply a slightly higher future P/E multiple in their models.Mise à jour du récit • Mar 17
NPCE: Expanded Epilepsy Indication And Guidance Reaffirmation Will Support More Optimistic Outlook
Analysts increased their price target on NeuroPace by about $0.45 to $19.88, citing updated assumptions around revenue growth, profit margins, the discount rate, and future P/E expectations. Analyst Commentary Bullish Takeaways Bullish analysts view the higher price target of about $19.88 as better aligned with their revised expectations for revenue growth and margin progress in the current model.Mise à jour du récit • Mar 03
NPCE: Refined Risk And Margin Outlook Will Support Future Upside Potential
Analysts lifted their price target on NeuroPace by $1, citing updated assumptions around the discount rate, profit margin, and future P/E that refine how they view the company’s risk and earnings potential. Analyst Commentary Recent Street research points to a more constructive tone around NeuroPace, with bullish analysts fine tuning their models rather than making wholesale changes.Mise à jour du récit • Feb 17
NPCE: Future Returns Will Reflect Trial Data Strength And Execution Risk
Analysts have raised their price target for NeuroPace by about $1 to approximately $16, reflecting updated assumptions around revenue growth, profit margins, and a lower future P/E multiple. Analyst Commentary Even with the roughly $1 move in the price target to about $16, some research commentary still reads as cautious rather than outright bullish.Mise à jour du récit • Feb 03
NPCE: Updated Seizure Trial Data Will Support A More Optimistic Outlook
Analysts have nudged their price target on NeuroPace higher to about US$19.43 from roughly US$17.13, citing updated assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E that are consistent with recent Street research. Analyst Commentary Analysts updating their models around NeuroPace are using the revised price target to reflect refreshed assumptions on valuation, growth expectations, and execution risks rather than a wholesale change in thesis.Mise à jour du récit • Jan 20
NPCE: Broader Epilepsy Indication And Trial Evidence Will Support Future Upside
Analysts now see NeuroPace as fairly valued around US$22.00 per share. They have made only slight tweaks to assumptions for discount rate, revenue growth, profit margin and future P/E, refining rather than overhauling their previous price target view.Article d’analyse • Jan 09
NeuroPace (NASDAQ:NPCE) Has Debt But No Earnings; Should You Worry?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Mise à jour du récit • Jan 06
NPCE: Expanded Epilepsy Indication And Trial Data Will Support Bullish Outlook
Analysts lifted their price target on NeuroPace from US$20.00 to US$22.00, citing changes in their fair value estimate along with updated assumptions for discount rate, revenue growth, profit margin and future P/E. What's in the News NeuroPace filed a Premarket Approval Supplement with the U.S. FDA to expand the labeled indication for its RNS System to antiseizure medication resistant idiopathic generalized epilepsy with generalized tonic clonic seizures, supported by preliminary NAUTILUS trial data showing a 77% median reduction in GTC seizures at 18 months and a favorable safety profile.Mise à jour du récit • Dec 15
NPCE: Future Performance Will Reflect Trial Data Strength And Moderate Risk
Analysts have raised their price target on NeuroPace from 13.00 dollars to 15.00 dollars. This reflects modestly lower perceived risk, slightly stronger long term margin potential, and still supportive valuation multiples despite a tempered revenue growth outlook.Article d’analyse • Nov 19
Revenues Tell The Story For NeuroPace, Inc. (NASDAQ:NPCE) As Its Stock Soars 25%
Despite an already strong run, NeuroPace, Inc. ( NASDAQ:NPCE ) shares have been powering on, with a gain of 25% in the...Article d’analyse • Sep 19
NeuroPace, Inc. (NASDAQ:NPCE) Looks Just Right With A 25% Price Jump
Those holding NeuroPace, Inc. ( NASDAQ:NPCE ) shares would be relieved that the share price has rebounded 25% in the...Article d’analyse • Aug 14
NeuroPace, Inc. (NASDAQ:NPCE) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
NasdaqGM:NPCE 1 Year Share Price vs Fair Value Explore NeuroPace's Fair Values from the Community and select yours...Seeking Alpha • Jun 29
NeuroPace: Volatile, Uncertain, But Promising
Summary NeuroPace has shown strong sales growth in its core drug-resistant epilepsy market, but remains unprofitable due to ongoing R&D expenses. Recent topline momentum is impressive, with 2024 guidance raised and sales growth accelerating, yet operating losses have stopped narrowing and even increased. The NAUTILUS trial failed to meet primary endpoints for generalized epilepsy, a major setback that limits near-term market expansion potential. Despite a reasonable sales multiple and recent financing, the failed trial and persistent losses make me cautious and hesitant to increase my position. Read the full article on Seeking AlphaArticle d’analyse • Jun 19
Is NeuroPace (NASDAQ:NPCE) Weighed On By Its Debt Load?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Article d’analyse • May 13
NeuroPace, Inc. (NASDAQ:NPCE) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable
NeuroPace, Inc. ( NASDAQ:NPCE ) shareholders would be excited to see that the share price has had a great month...
Nouveau récit • Mar 30
Expanding Level 4 Epilepsy Centers Will Unlock Future Potential
Expanding presence in epilepsy centers and Project CARE may significantly boost revenue by increasing market penetration and service delivery.Article d’analyse • Mar 07
NeuroPace, Inc. (NASDAQ:NPCE) Annual Results: Here's What Analysts Are Forecasting For This Year
It's been a sad week for NeuroPace, Inc. ( NASDAQ:NPCE ), who've watched their investment drop 11% to US$11.18 in the...Article d’analyse • Jan 24
NeuroPace, Inc. (NASDAQ:NPCE) Looks Just Right With A 26% Price Jump
Despite an already strong run, NeuroPace, Inc. ( NASDAQ:NPCE ) shares have been powering on, with a gain of 26% in the...Article d’analyse • Dec 04
After Leaping 90% NeuroPace, Inc. (NASDAQ:NPCE) Shares Are Not Flying Under The Radar
NeuroPace, Inc. ( NASDAQ:NPCE ) shares have had a really impressive month, gaining 90% after a shaky period beforehand...Article d’analyse • Nov 14
Here's What Analysts Are Forecasting For NeuroPace, Inc. (NASDAQ:NPCE) After Its Third-Quarter Results
A week ago, NeuroPace, Inc. ( NASDAQ:NPCE ) came out with a strong set of quarterly numbers that could potentially lead...Article d’analyse • Nov 07
Does NeuroPace (NASDAQ:NPCE) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Article d’analyse • Aug 03
NeuroPace, Inc. (NASDAQ:NPCE) Screens Well But There Might Be A Catch
It's not a stretch to say that NeuroPace, Inc.'s ( NASDAQ:NPCE ) price-to-sales (or "P/S") ratio of 2.9x right now...Article d’analyse • Apr 12
Is NeuroPace (NASDAQ:NPCE) Weighed On By Its Debt Load?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • Feb 25
NeuroPace: Picking Up The Pace
Summary NeuroPace shares have doubled since September 2023, driven by strong operating momentum. The company aims to improve the lives of epilepsy patients with its remote monitoring system, which has the potential for significant growth. Following the share price rally, I have trimmed my position but continue to hold a long position due to the company's potential and operating momentum. Read the full article on Seeking AlphaArticle d’analyse • Jan 22
Why Investors Shouldn't Be Surprised By NeuroPace, Inc.'s (NASDAQ:NPCE) 58% Share Price Surge
Despite an already strong run, NeuroPace, Inc. ( NASDAQ:NPCE ) shares have been powering on, with a gain of 58% in the...Article d’analyse • Apr 17
NeuroPace, Inc. (NASDAQ:NPCE) Stock Rockets 39% But Many Are Still Ignoring The Company
NeuroPace, Inc. ( NASDAQ:NPCE ) shares have continued their recent momentum with a 39% gain in the last month alone...Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$22m |
| Dec 31 2025 | US$2m | US$568k | -US$21m |
| Sep 30 2025 | n/a | n/a | -US$24m |
| Jun 30 2025 | n/a | n/a | -US$26m |
| Mar 31 2025 | n/a | n/a | -US$25m |
| Dec 31 2024 | US$3m | US$529k | -US$27m |
| Sep 30 2024 | n/a | n/a | -US$28m |
| Jun 30 2024 | n/a | n/a | -US$30m |
| Mar 31 2024 | n/a | n/a | -US$32m |
| Dec 31 2023 | US$2m | US$248k | -US$33m |
Rémunération vs marché: La rémunération totale de Joel ($USD 2.41M ) est dans la moyenne des entreprises de taille similaire sur le marché US ($USD 2.63M ).
Rémunération et revenus: La rémunération de Joel a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.
PDG
Joel Becker (58 yo)
2.9yrs
Titularisation
US$2,408,567
Compensation
Mr. Joel D. Becker serves as CEO & Director of at NeuroPace, Inc. since July 10, 2023 and serves as its President. He had been President of Cardiac Rhythm Management & Neuromodulation at Integer Holdings C...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| CEO, President & Director | 2.9yrs | US$2.41m | 0.41% $ 2.2m | |
| Chief Financial Officer | 1yr | US$1.88m | pas de données | |
| Chief Medical Officer | 21.9yrs | US$1.03m | 0.15% $ 818.8k | |
| Advisor | 1yr | US$846.31k | 0.23% $ 1.3m | |
| Chief of Operations & Development | 2.1yrs | pas de données | pas de données | |
| Head of Investor Relations | no data | pas de données | pas de données | |
| General Counsel & Corporate Secretary | 2.2yrs | pas de données | pas de données | |
| Vice President of Marketing | 1.4yrs | pas de données | pas de données | |
| Senior Vice President of Sales | 1.1yrs | pas de données | pas de données | |
| Vice President of Human Resources | 1.7yrs | pas de données | pas de données | |
| VP & Controller | less than a year | pas de données | pas de données |
1.5yrs
Durée moyenne de l'emploi
61.5yo
Âge moyen
Gestion expérimentée: L'équipe de direction de NPCE n'est pas considérée comme expérimentée (ancienneté moyenne 1.5 ans), ce qui suggère une nouvelle équipe.
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| CEO, President & Director | 2.9yrs | US$2.41m | 0.41% $ 2.2m | |
| Independent Director | 29.4yrs | US$123.70k | 1.07% $ 5.7m | |
| Chairman of the Board | 28.6yrs | US$173.70k | 1.75% $ 9.3m | |
| Independent Director | 3.4yrs | US$126.20k | 0.044% $ 232.2k | |
| Independent Director | 1.4yrs | US$257.20k | 0.0085% $ 45.2k | |
| Independent Director | 13.4yrs | US$136.20k | 0.12% $ 643.5k | |
| Board Observer | no data | pas de données | pas de données | |
| Independent Director | 4.6yrs | US$138.70k | 0.0085% $ 45.2k | |
| Independent Director | 5.2yrs | US$138.70k | 0.065% $ 344.6k |
4.9yrs
Durée moyenne de l'emploi
58yo
Âge moyen
Conseil d'administration expérimenté: Les membres du conseil d'administration de NPCE sont considérés comme expérimentés (ancienneté moyenne 4.9 ans).
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/06/09 09:40 |
| Cours de l'action en fin de journée | 2026/06/09 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
NeuroPace, Inc. est couverte par 13 analystes. 8 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Michael Polark | Baird |
| Sarah James | Cantor Fitzgerald & Co. |
| Ross Osborn | Cantor Fitzgerald & Co. |